Warrants of series TO6 were subscribed to approximately 94 percent and Lumito receives approximately SEK 12.6 million
Lumito AB (publ) ("Lumito" or the "Company") today announces the outcome of the exercise of warrants of series TO6, which were issued in connection to an issue and loan financing during the fourth quarter of 2023. In total, 32,206,770 warrants were exercised, corresponding to approximately 94 percent of the total number of outstanding warrants, for […]
Members of Lumitos board and management team intend to exercise warrants of series TO6
Members of the board and management that hold warrants of series TO6 Lumito AB (publ) ("Lumito" or the "Company") intend to exercise 575,512 warrants to a value of SEK 224 thousand. The board and management team intends to exercise warrants, directly or via companies, according to the following: Kerstin Jakobsson (Chair of the Board) – […]
The last day of trading with the warrants of series TO6 in Lumito AB is today, November 12, 2024
Today, November 12, 2024, is the last day of trading with the warrants of series TO6 in Lumito AB (publ) (“Lumito” or the “Company”). The exercise period for the warrants runs up to and including November 15, 2024. Each warrant of series TO6 gives the owner the right to subscribe for one (1) new share […]
Lumito signs Letter of Intent with Scientific Advisor
Lumito has signed a Letter of Intent with pathologist Paul Waring for strategic guidance regarding the market need for Lumito's products and future product development. Paul Waring is a highly experienced pathologist with approximately 35 years of leading and global experience in the hospital sector, academia, and industry. He initiated and drove the partnership between […]
Lumito AB signs a Letter of Intent with Katana Labs GmbH
Lumito has signed a "Letter of Intent” with Katana Labs in Germany to offer a cloud and AI-based image analysis solution to Lumito's future customers with "scanning-service agreements". For potential customers to easily evaluate Lumito's product SCIZYS, a "scanning service" is offered. This enables customers to evaluate the benefits of SCIZYS without first investing in […]
Lumito has CE-marked its first product SCIZYS
Lumito has CE-marked its first product, SCIZYS. This is an important milestone for Lumito and means that sales for the histopathological research market can begin. SCIZYS S1 now fulfils all the relevant provisions of the EC Machinery Directive 2006/42/EC. The internal work required to be able to CE mark the product after receiving the final […]
Research group at the Tyndall National Institute got an article published on the use of up-converting nanoparticles
A research group at the Tyndall National Institute in Cork, Ireland, got an article published in Biomedical Optics Express titled "High contrast breast cancer biomarker semi-quantification and immunohistochemistry imaging using upconverting nanoparticles". The research study uses Lumito's technology with up-converting nanoparticles (UCNPs). The article examines the use of UCNPs to distinguish different levels of HER2 […]
Lumito attends the Digital Pathology & AI Congress in London
On December 7–8, Lumito will exhibit with a booth at the annual Digital Pathology & AI Congress in London. The presence is part of the company's branding work within the company's primary target group ahead of the upcoming launch of SCIZYS. – It is important for us to build trust around our brand and product. […]
Lumito has started an internal pilot study for multiplexing
Lumito has started a pilot study where the aim is to investigate the possibilities of multiplexing by adding another nanoparticle label to the company's unique UCNP-based technology. There is a pronounced need from the market regarding requests for multiplexing to facilitate further and streamline the work within tissue analysis. Lumito already offers multiplexing with today's […]
Watch Mattias Lundin’s presentation at the BioStock Life Science Summit on October 25
On October 25, Mattias Lundin, Lumito's CEO, presented the company and the strategy going forward at the BioStock Life Science Summit in Lund. The presentation can be viewed afterwards here: Lumitos Presentation at the BioStock Life Science Summit October 25, 2023 For further information, please contact: Mattias Lundin, CEO LumitoE-mail: ml@lumito.sePh: +46 76 868 45 09 […]
